Last updated on November 2018

Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid


Brief description of study

This is an open label multicenter study to evaluate the safety and tolerability of multiple doses(3 monthly IV infusions) of SEL-212 ( a combination of pegsiticase( SEL-037) and SVP-rapamycin (SEL-110)) followed by multiple doses (2 monthly IV infusions) of pegsiticase (SEL-037) alone for a total of 5 treatment cycles in subjects with symptomatic gout and hyperuricemia. Additional subjects will be treated with multiple doses( 5 monthly IV infusions) of pegsiticase (SEL-037) alone.

Subjects will be monitored for safety endpoints through the 5th treatment cycle plus 30 days .Pharmacokinetic samples will drawn a pre-determined time points in addition to weekly serum uric acid levels.

Detailed Study Description

This is an open label multicenter study to evaluate the safety and tolerability of multiple doses(3 monthly IV infusions) of SEL-212( a combination of pegsiticase( SEL-037) and SVP-rapamycin (SEL-110)) followed by multiple doses (2 monthly IV infusions) of pegsiticase (SEL-037) alone for a total of 5 treatment cycles in subjects with symptomatic gout and hyperuricemia. Additional subjects will be treated with multiple doses( 5 monthly IV infusions) of pegsiticase (SEL-037) alone.

Uricase is an enzyme that converts uric acid to the readily soluble allantoin that is then excreted and SEL-110 is designed to prevent unwanted anti-drug-antibodies (ADAs) from forming. All subjects will be monitored for safety and tolerability to drug throughout the study on a weekly schedule. Pharmacokinetic and pharmacodynamic parameters will at specific timepoints to monitor for continued efficacy. Pharmacodynamic parameters measured include uric acid levels and levels of ADAs.

The study duration per enrolled subject will be approximately 6 months including a 1 month screening period followed by 5 treatment cycles and an end of treatment visit which will occur 30 days after the last IV infusion .

Clinical Study Identifier: NCT02959918

Contact Investigators or Research Sites near you

Start Over

Earl E Sands, MD

Anaheim Clinical Trials
Anaheim, CA United States

Earl E Sands, MD

Clinical Research of West Florida
Clearwater, FL United States

Earl E Sands, MD

Omega Research Consultants LLC
DeBary, FL United States

Earl E Sands, MD

Compass Research LLC
Orlando, FL United States

Earl E Sands, MD

East-West Medical Research Institute
Honolulu, HI United States

Earl E Sands, MD

Advanced Clinical Research
Boise, ID United States

Earl E Sands, MD

L-MARC
Louisville, KY United States

Earl E Sands, MD

Triad Clinical Trials LLC
Greensboro, NC United States

Earl E Sands, MD

New Horizons Clinical Research
Cincinnati, OH United States

Earl E Sands, MD

Altoona Center for Clinical Research
Duncansville, PA United States

Earl E Sands, MD

Advanced Clinical Research
West Jordan, UT United States

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.